These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 23052255

  • 1. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.
    Clin Cancer Res; 2012 Dec 15; 18(24):6599-608. PubMed ID: 23052255
    [Abstract] [Full Text] [Related]

  • 2. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H.
    Lung Cancer; 2014 May 15; 84(2):121-6. PubMed ID: 24629636
    [Abstract] [Full Text] [Related]

  • 3. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.
    J Mol Diagn; 2014 Mar 15; 16(2):229-43. PubMed ID: 24418728
    [Abstract] [Full Text] [Related]

  • 4. Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
    Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.
    Clin Chem; 2017 Mar 15; 63(3):751-760. PubMed ID: 28073897
    [Abstract] [Full Text] [Related]

  • 5. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y.
    Nat Med; 2012 Feb 12; 18(3):378-81. PubMed ID: 22327623
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL.
    Mod Pathol; 2015 Apr 12; 28(4):468-79. PubMed ID: 25234288
    [Abstract] [Full Text] [Related]

  • 7. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.
    Lung Cancer; 2014 Feb 12; 83(2):168-73. PubMed ID: 24380695
    [Abstract] [Full Text] [Related]

  • 8. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.
    Ann Oncol; 2013 Sep 12; 24(9):2364-70. PubMed ID: 23788756
    [Abstract] [Full Text] [Related]

  • 9. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ, Sohn I, Cho JH, Lee HY, Kim JH, Choi YL, Kim H, Lee G, Lee KS, Kim J.
    Medicine (Baltimore); 2015 Oct 12; 94(41):e1753. PubMed ID: 26469915
    [Abstract] [Full Text] [Related]

  • 10. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.
    Lab Invest; 2018 Mar 12; 98(3):371-379. PubMed ID: 29251734
    [Abstract] [Full Text] [Related]

  • 11. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y.
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep 12; 44(9):639-43. PubMed ID: 26705279
    [Abstract] [Full Text] [Related]

  • 12. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, Sakao Y, Yatabe Y.
    Cancer; 2017 May 15; 123(10):1731-1740. PubMed ID: 28177518
    [Abstract] [Full Text] [Related]

  • 13. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y, Kohsaka S, Hayashi T, Akaike K, Kurisaki-Arakawa A, Sato S, Kobayashi E, Mizuno S, Ueno T, Morii T, Okuma T, Kurihara T, Hasegawa N, Sano K, Sasa K, Okubo T, Kim Y, Mano H, Saito T.
    Clin Orthop Relat Res; 2021 Apr 01; 479(4):838-852. PubMed ID: 33196586
    [Abstract] [Full Text] [Related]

  • 14. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
    Kim JO, Lee J, Shin JY, Oh JE, Jung CK, Park JK, Sung SW, Bae SJ, Min HJ, Kim D, Park JY, Kang JH.
    Diagn Pathol; 2015 Aug 14; 10():143. PubMed ID: 26268359
    [Abstract] [Full Text] [Related]

  • 15. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT.
    J Thorac Oncol; 2017 May 14; 12(5):872-877. PubMed ID: 28088512
    [Abstract] [Full Text] [Related]

  • 16. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S, Yan B, Zheng J, Zhao J, Zhou J.
    Oncotarget; 2016 Sep 27; 7(39):63758-63766. PubMed ID: 27563816
    [Abstract] [Full Text] [Related]

  • 17. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M.
    Mol Cancer Res; 2014 Jan 27; 12(1):111-8. PubMed ID: 24296758
    [Abstract] [Full Text] [Related]

  • 18. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M.
    Lung Cancer; 2016 Apr 27; 94():22-7. PubMed ID: 26973202
    [Abstract] [Full Text] [Related]

  • 19. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
    Borrelli N, Giannini R, Proietti A, Alì G, Pelliccioni S, Niccoli C, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G.
    Lung Cancer; 2013 Sep 27; 81(3):377-381. PubMed ID: 23891510
    [Abstract] [Full Text] [Related]

  • 20. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
    Melchior L, Hirschmann A, Hofman P, Bontoux C, Concha A, Mrabet-Dahbi S, Vannuffel P, Watkin E, Putzová M, Scarpino S, Cayre A, Martin P, Stoehr R, Hartmann A.
    Virchows Arch; 2024 Apr 27; 484(4):677-686. PubMed ID: 38492039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.